Gene therapy experts at Nationwide Children's Hospital have recognized there is a need for constructing Adeno-Associated Virus (AAV) AAV vectors that display immunogenic peptides/polypeptides or display targeting peptides that promote delivery of DNA to a specific target cell. Our inventors have elucidated regions of the AAV2 capsid protein that are amenable to insertion of peptides that cause altered characteristics in comparison to wildtype AAV, including, but not limited to, altered cellular tropism and/or antigenic properties. Our experts' technology could vastly increase the utility of AAV vectors for clinical gene transfer. This technology is covered in US issued patents 6,962,815 and 7,749,492.